🔗 Share this article World Health Organization Raises Concern Over Critical Scarcity of Weight-Loss Jabs Less than 10% of people eligible to benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it publishes its initial recommendations on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments. According to estimates, more than two billion are projected to be obese by 2030 unless action is taken. "Our new guidelines acknowledges that obesity is a chronic disease that can be managed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread access to the treatments that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Supply Crisis Even under the present best projected scenario, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization. The advice urges countries and companies to increase access, through approaches like licensing agreements. A patent on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026. How Obesity Injections Work These medications imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals eat less. Individuals usually begin shedding pounds within a few weeks of starting on the regular doses. Evidence indicates users may put most of the weight back on after a year of stopping the drug, when their typical hunger return. Being overweight or obese elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, stroke, and specific cancers. Obesity impacts people in every country and was associated with millions of fatalities worldwide in 2024, per the WHO.
Less than 10% of people eligible to benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it publishes its initial recommendations on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments. According to estimates, more than two billion are projected to be obese by 2030 unless action is taken. "Our new guidelines acknowledges that obesity is a chronic disease that can be managed with thorough and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are major obstacles to widespread access to the treatments that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Supply Crisis Even under the present best projected scenario, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization. The advice urges countries and companies to increase access, through approaches like licensing agreements. A patent on the active ingredient – the primary ingredient of a leading brand – is set to lapse in a number of countries in 2026. How Obesity Injections Work These medications imitate a biological compound to delay gastric emptying, suppress the appetite and enhance feelings of fullness so individuals eat less. Individuals usually begin shedding pounds within a few weeks of starting on the regular doses. Evidence indicates users may put most of the weight back on after a year of stopping the drug, when their typical hunger return. Being overweight or obese elevates your likelihood for contracting health problems, like diabetes, cardiovascular issues, stroke, and specific cancers. Obesity impacts people in every country and was associated with millions of fatalities worldwide in 2024, per the WHO.